Back to search
FDAFDA · Food and drugs·Recall number D-0309-2022

EPINEPHIrine in 0.9% Sodium Chloride Injection, 5 mg per 250 mL (20 mcg per mL), Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-052-01.

Published January 5, 2022 · Recall initiated: November 12, 2021

Summary

FDA records drug Class II recall D-0309-2022, published January 5, 2022 and initiated November 12, 2021. Recalling firm: SterRx, LLC; Status: Terminated; Reported quantity: 7548 bags; Lot: S21255/BXA 22-Jan-22 S21264/BXH 29-Jan-22 S21328/BZO 10-Mar-22. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SterRx, LLC
Distributor
U.S.A. Nationwide
Lot
S21255/BXA 22-Jan-22 S21264/BXH 29-Jan-22 S21328/BZO 10-Mar-22
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was EPINEPHIrine in 0.9% Sodium Chloride Injection, 5 mg per 250 mL (20 mcg per mL), Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-052-01. recalled?

Yes. FDA published recall D-0309-2022 on January 5, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release